Ambroxol Syrup for Respiratory Conditions

Mechanism and Classification

Ambroxol is classified as a mucoregulator that reduces mucus viscosity by altering sialomucin synthesis, helping to improve sputum clearance in respiratory conditions 1, 2
It can be administered orally as syrup, parenterally, or by nebulization 1

High-dose mucolytic therapy (including ambroxol) may reduce hospitalization rates and exacerbation frequency in patients with moderate to severe COPD 2, 3
For patients with moderate or severe COPD and recurrent exacerbations despite optimal inhaled therapy, mucolytic agents like ambroxol may be considered to prevent future exacerbations 2, 4
Guidelines do not recommend routine use of mucokinetic agents for acute bronchitis due to inconsistent effects 5
Some evidence suggests ambroxol may reduce episodes of acute upper respiratory diseases, but this is not a widely recommended indication due to limited high-quality evidence 6

European Respiratory Society guidelines note that widespread use of mucolytic agents (including ambroxol) cannot be recommended based on current evidence 1, 7
Most clinical trials showing benefit were conducted with N-acetylcysteine rather than ambroxol specifically 4
The beneficial effect of mucolytic therapy on COPD exacerbations was primarily seen with high-dose therapy 3
Patients with moderate or severe airflow obstruction are most likely to benefit 2

Consider ambroxol for patients with COPD who have frequent exacerbations despite optimal inhaled therapy 2, 4
Not recommended as first-line therapy for uncomplicated acute bronchitis 5
May be more appropriate for patients with copious and tenacious mucus production 1